[1] |
NAGHAVI M, WANG H, LOZANO R, et al. Global,regional,and national age-sex specific all-cause and cause-specific mortality for 240 causes of death,1990-2013:A systematic analysis for the Global Burden of Disease Study 2013[J]. The Lancet, 2015, 385(9963):117-171. doi:10.1016/S0140-6736(14)61682-2.
|
[2] |
HEUSCH G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective[J]. Nat Rev Cardiol, 2020, 17(12):773-789. doi:10.1038/s41569-020-0403-y.
|
[3] |
KONIJNENBERG L S F, DAMMAN P, DUNCKER D J, et al. Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction[J]. Cardiovasc Res, 2020, 116(4):787-805. doi:10.1093/cvr/cvz301.
|
[4] |
HAUSENLOY D J, KHARBANDA R K, MØLLER U K, et al. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI):a single-blind randomised controlled trial[J]. Lancet, 2019, 394(10207):1415-1424. doi:10.1016/S0140-6736(19)32039-2.
|
[5] |
CHEN Z, WU J, LI S, et al. Inhibition of myocardial cell apoptosis is important mechanism for ginsenoside in the limitation of myocardial ischemia/reperfusion injury[J]. Front Pharmacol, 2022, 13:806216. doi:10.3389/fphar.2022.806216.
|
[6] |
QIN H, LI S, LIU Z. Protective effect of shexiang baoxin pill on myocardial ischemia/reperfusion injury in patients with STEMI[J]. Front Pharmacol, 2021, 12:721011. doi:10.3389/fphar.2021.721011.
|
[7] |
GUO J, QIN Z, HE Q, et al. Shexiang baoxin pill for acute myocardial infarction:clinical evidence and molecular mechanism of antioxidative stress[J]. Oxid Med Cell Longev, 2021, 2021:7644648. doi:10.1155/2021/7644648.
|
[8] |
TIAN P P, LI J, GAO J, et al. Efficacy and safety of the shexiang Baoxin Pill for the treatment of coronary artery disease not amenable to revascularisation:study protocol for a randomised,placebo-controlled,double-blinded trial[J]. BMJ Open, 2018, 8(2):e018052. doi:10.1136/bmjopen-2017-018052.
|
[9] |
GE J B, FAN W H, ZHOU J, et al. Efficacy and safety of shexiang baoxin pill (MUSKARDIA) in patients with stable coronary artery disease:a multicenter,double-blind,placebo-controlled phase Ⅳ randomized clinical trial[J]. Chin Med J (Engl), 2020, 134(2):185-192. doi:10.1097/CM9.0000000000001257.
|
[10] |
WEI J, LIU S, WANG X, et al. Efficacy and safety of shexiang baoxin pill for coronary heart disease after percutaneous coronary intervention:A systematic review and meta-analysis[J]. Evid Based Complement Alternat Med, 2021, 2021:2672516. doi:10.1155/2021/2672516.
|
[11] |
WU G, CHEN L, GU Y, et al. Exploring the mechanism underlying the cardioprotective effect of shexiang baoxin pill on acute myocardial infarction rats by comprehensive metabolomics[J]. J Ethnopharmacol, 2020, 259:113001. doi:10.1016/j.jep.2020.113001.
|
[12] |
LU L, QIN Y, ZHANG X, et al. Shexiang baoxin pill alleviates the atherosclerotic lesions in mice via improving inflammation response and inhibiting lipid accumulation in the arterial wall[J]. Mediators Inflamm, 2019, 2019:6710759. doi:10.1155/2019/6710759.
|
[13] |
PHAM D C, NGUYEN H C, NGUYEN T L, et al. Optimization of ultrasound-assisted extraction of flavonoids from celastrus hindsii leaves using response surface methodology and evaluation of their antioxidant and antitumor activities[J]. Biomed Res Int, 2020, 2020:3497107. doi:10.1155/2020/3497107.
|
[14] |
CHANG W, HAN L, HUANG H, et al. Simultaneous determination of four volatile compounds in rat plasma after oral administration of Shexiang Baoxin Pill (SBP) by HS-SPDE-GC-MS/MS and its application to pharmacokinetic studies[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2014, 963:47-53.
|
[15] |
HAUSENLOY D J, YELLON D M. Myocardial ischemia-reperfusion injury:a neglected therapeutic target[J]. J Clin Invest, 2013, 123(1):92-100. doi:10.1172/JCI62874.
|
[16] |
MCLEOD S L, IANSAVICHENE A E, CHESKES S. Remote ischemic perconditioning to reduce reperfusion injury during acute ST‐segment-elevation myocardial infarction:A systematic review and meta‐analysis[J]. J Am Heart Assoc, 2017, 6(5):e005522. doi:10.1161/JAHA.117.005522.
|
[17] |
GARCÍA-RUÍZ J M, FERNANDEZ-JIMENEZ R, GARCIA-ALVAREZ A, et al. Impact of the timing of metoprolol administration during STEMI on infarct size and ventricular function[J]. J Am Coll Cardiol, 2016, 67(18):2093-2104. doi:10.1016/j.jacc.2016.02.050.
|
[18] |
LI J, SUN D, LI Y. Novel findings and therapeutic targets on cardioprotection of ischemia/reperfusion injury in STEMI[J]. Curr Pharm Des, 2019, 25(35):3726-3739. doi:10.2174/1381612825666191105103417.
|
[19] |
LI L, WANG Y, GUO R, et al. Ginsenoside Rg3-loaded,reactive oxygen species-responsive polymeric nanoparticles for alleviating myocardial ischemia-reperfusion injury[J]. J Control Release, 2020, 317:259-272. doi:10.1016/j.jconrel.2019.11.032.
|
[20] |
LV X, LU P, HU Y, et al. miR-346 inhibited apoptosis against myocardial ischemia-reperfusion injury via targeting bax in rats.[J]. Drug Des Devel Ther, 2020, 14:895-905. doi:10.2147/DDDT.S245193.
|
[21] |
YAO H, XIE Q, HE Q, et al. Pretreatment with panaxatriol saponin attenuates mitochondrial apoptosis and oxidative stress to facilitate treatment of myocardial ischemia-reperfusion injury via the regulation of Keap1/Nrf2 activity[J]. Oxid Med Cell Longev, 2022, 2022:9626703. doi:10.1155/2022/9626703.
|
[22] |
LU Y, LI S Y, LOU H. Patchouli alcohol protects against myocardial ischaemia-reperfusion injury by regulating the Notch1/Hes1 pathway[J]. Pharm Biol, 2022, 60(1):949-957. doi:10.1080/13880209.2022.2064881.
|